KMT2A and acute myeloid leukemia: identified several potential biomarkers for the clinic: AT-rich interaction domain 2, lysine methyltransferase 2A, and synaptotagmin binding cytoplasmic RNA interacting protein; all of these could be used to predict the prognosis of t (8;21) AML (104).